Get started
Award

#FO2017-0243

Funded outputs count: 115
Funder award ID: #FO2017-0243
OpenAlex ID: G180825096
Spatiotemporal characterization of Alzheimer disease pathology in living human brain tissue
2026 · Aram Aslanyan, Soumya Mukherjee, et al. · Nature Communications · 1
PDF
CSF p-tau205: a biomarker of Alzheimer’s disease progression and biological staging
2026 · Juan Lantero-Rodriguez, Shorena Janelidze, et al. · Molecular Psychiatry
PDF
Astrocyte reactivity modifies the effects of locus coeruleus norepinephrine‐related dysfunction on tau and its impact on cognition
2026 · Prokopis C. Prokopiou, Maxime Van Egroo, et al. · Alzheimer s & Dementia
Analytical and clinical validation of the Lumipulse G plasma p‐tau217 assay for clinical implementation
2026 · Burak Arslan, Johan Gobom, et al. · Alzheimer s & Dementia · 4
Cerebrospinal fluid NPTX2/p‐tau ratio as a biomarker for cognitive decline in neurodegenerative diseases
2026 · Bárbara Fernandes Gomes, Mathias Sauer, et al. · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · 1
Glymphatic dysfunction links vascular pathology to Alzheimer’s biomarkers and cognitive decline
2026 · Sung Hoon Kang, Seongmi Kim, et al. · Alzheimer s Research & Therapy · 9
Early functional changes and plasma GFAP in Swedish families with Autosomal Dominant Alzheimer’s disease mutations
2026 · Emma S. Luckett, Mariola Zapater-Fajari, et al. · Translational Psychiatry · 1
PDF
Association of acute blood biomarkers with diffusion tensor imaging and outcome in patients with traumatic brain injury presenting with GCS of 13–15
2025 · Malla Mononen, Mehrbod Mohammadian, et al. · NeuroImage Clinical · 2
APOE ɛ4 carriership determines a faster plasma p‐tau217 progression in Aβ‐positive individuals
2025 · Marcel S. Woo, Arthur C Macedo, et al. · Alzheimer s & Dementia · 4
Diagnostic Value of Serum p-tau217 in Alzheimer Disease: Equal to Plasma in Levels and Clinical Utility?
2025 · Andrea L Benedet, Burak Arslan, et al. · Clinical Chemistry · 14
Cerebrospinal fluid proteomic associations of APOE genotypes reveal distinct protective and risk mechanisms for Alzheimer's disease
2025 · Eleonora M. Vromen, Senne B. Lageman, et al. · Alzheimer s & Dementia · 8
PDF
Predicting cognitive decline with amyloid‐PET, plasma p‐tau217, Aβ42/40, and p‐tau217/Aβ42 in a community‐based cohort – relevance for clinical trial enrollment
2025 · Dario Bachmann, Maha Wybitul, et al. · Alzheimer s & Dementia · 5
PDF
Blood pressure and Alzheimer’s disease biomarkers in cognitively unimpaired adults: a multicenter study
2025 · Mariona Osset-Malla, Aitana Martínez-Velasco, et al. · The Journal of Prevention of Alzheimer s Disease · 8
Brain and CSF Alzheimer’s Biomarkers Are Associated with SERPINE1 Gene Expression
2025 · Cynthia Picard, Henrik Zetterberg, et al. · Genes · 4
PDF
Neurofilament, but not Alzheimer disease biomarkers in the acute phase correlate with cognitive performance after cardiac arrest
2025 · Johannes Lorentzson, Gisela Lilja, et al. · Resuscitation Plus · 1
Chemical imaging delineates Aβ plaque polymorphism across the Alzheimer’s disease spectrum
2025 · Srinivas Koutarapu, Junyue Ge, et al. · Nature Communications · 30
Plasma p‐tau212 as a biomarker of sporadic and Down syndrome Alzheimer's disease
2025 · Przemysław R. Kac, Daniel Alcolea, et al. · Alzheimer s & Dementia · 22
PDF
Data‐driven evaluation of suitable immunogens for improved antibody selection
2025 · Katharina Waury, Hlin Kvartsberg, et al. · Protein Science · 1
Synaptic protein CSF levels relate to memory scores in individuals without dementia
2025 · Kirsten E. J. Wesenhagen, Diederick M. de Leeuw, et al. · Alzheimer s Research & Therapy · 4
Tau levels in platelets isolated from Huntington’s disease patients serve as a biomarker of disease severity
2025 · Melanie Alpaugh, Juan Lantero-Rodriguez, et al. · Journal of Neurology · 7
Considerations in the clinical use of amyloid PET and CSF biomarkers for Alzheimer's disease
2025 · Antoine Leuzy, Ariane Bollack, et al. · Alzheimer s & Dementia · 112
Regional brain structural alterations in reward and salience networks in asthma
2025 · Danielle Carrol, William W. Busse, et al. · Brain Behavior and Immunity · 6
PDF
Evaluation of two plasma‐based proteotyping assays against APOE ε4 genotyping in a memory clinic setting: The Gothenburg H70 Clinical Studies
2025 · Anna Dittrich, Kaj Blennow, et al. · Alzheimer s & Dementia · 20
PDF
Loneliness and Biomarkers of Alzheimer’s Disease, Axonal Damage, and Astrogliosis: A Coordinated Analysis of Two Longitudinal Cohorts
2025 · Antonio Terracciano, Keenan A Walker, et al. · The Journals of Gerontology Series B · 12
Sex differences in the relationships between 24-h rest-activity patterns and plasma markers of Alzheimer’s disease pathology
2024 · Maxime Van Egroo, Elise Beckers, et al. · Alzheimer s Research & Therapy · 13
PDF